Characterizing the ability of an ice recrystallization inhibitor to improve platelet cryopreservation.

Waters, L; Ben, R; Acker, JP; Padula, MP; Marks, DC; Johnson, L

Characterizing the ability of an ice recrystallization inhibitor to improve platelet cryopreservation.

Waters, L Ben, R Acker, JP Padula, MP Marks, DC Johnson, L

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Cryobiology, 2020, 96, pp. 152-158
Issue Date:: 2020-10

Closed Access

	Filename	Description	Size
	1-s2.0-S0011224020302388-main.pdf	Published version	4.14 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Waters, L
dc.contributor.author	Ben, R
dc.contributor.author	Acker, JP
dc.contributor.author	Padula, MP
dc.contributor.author	Marks, DC
dc.contributor.author	Johnson, L
dc.date.accessioned	2020-11-07T21:57:50Z
dc.date.available	2020-07-13
dc.date.available	2020-11-07T21:57:50Z
dc.date.issued	2020-10
dc.identifier.citation	Cryobiology, 2020, 96, pp. 152-158
dc.identifier.issn	0011-2240
dc.identifier.issn	1090-2392
dc.identifier.uri	http://hdl.handle.net/10453/143839
dc.description.abstract	Improving aspects of platelet cryopreservation would help ease logistical challenges and potentially expand the utility of frozen platelets. Current cryopreservation procedures damage platelets, which may be caused by ice recrystallization. We hypothesized that the addition of a small molecule ice recrystallization inhibitor (IRI) to platelets prior to freezing may reduce cryopreservation-induced damage and/or improve the logistics of freezing and storage. Platelets were frozen using standard conditions of 5-6% dimethyl sulfoxide (Me2SO) or with supplementation of an IRI, N-(2-fluorophenyl)-d-gluconamide (2FA), prior to storage at -80 °C. Alternatively, platelets were frozen with 5-6% Me2SO at -30 °C or with 3% Me2SO at -80 °C with or without 2FA supplementation. Supplementation of platelets with 2FA improved platelet recovery following storage under standard conditions (p = 0.0017) and with 3% Me2SO (p = 0.0461) but not at -30 °C (p = 0.0835). 2FA supplementation was protective for GPVI expression under standard conditions (p = 0.0011) and with 3% Me2SO (p = 0.0042). Markers of platelet activation, such as phosphatidylserine externalization and microparticle release, were increased following storage at -30 °C or with 3% Me2SO, and 2FA showed no protective effect. Platelet function remained similar regardless of 2FA, although functionality was reduced following storage at -30 °C or with 3% Me2SO compared to standard cryopreserved platelets. While the addition of 2FA to platelets provided a small level of protection for some quality parameters, it was unable to prevent alterations to the majority of in vitro parameters. Therefore, it is unlikely that ice recrystallization is the major cause of cryopreservation-induced damage.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Cryobiology
dc.relation.isbasedon	10.1016/j.cryobiol.2020.07.003
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	0601 Biochemistry and Cell Biology, 1116 Medical Physiology
dc.subject.classification	Biochemistry & Molecular Biology
dc.title	Characterizing the ability of an ice recrystallization inhibitor to improve platelet cryopreservation.
dc.type	Journal Article
utslib.citation.volume	96
utslib.location.activity	Netherlands
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1116 Medical Physiology
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	closed_access	*
dc.date.updated	2020-11-07T21:57:44Z
pubs.publication-status	Published
pubs.volume	96

Abstract:

Improving aspects of platelet cryopreservation would help ease logistical challenges and potentially expand the utility of frozen platelets. Current cryopreservation procedures damage platelets, which may be caused by ice recrystallization. We hypothesized that the addition of a small molecule ice recrystallization inhibitor (IRI) to platelets prior to freezing may reduce cryopreservation-induced damage and/or improve the logistics of freezing and storage. Platelets were frozen using standard conditions of 5-6% dimethyl sulfoxide (Me2SO) or with supplementation of an IRI, N-(2-fluorophenyl)-d-gluconamide (2FA), prior to storage at -80 °C. Alternatively, platelets were frozen with 5-6% Me2SO at -30 °C or with 3% Me2SO at -80 °C with or without 2FA supplementation. Supplementation of platelets with 2FA improved platelet recovery following storage under standard conditions (p = 0.0017) and with 3% Me2SO (p = 0.0461) but not at -30 °C (p = 0.0835). 2FA supplementation was protective for GPVI expression under standard conditions (p = 0.0011) and with 3% Me2SO (p = 0.0042). Markers of platelet activation, such as phosphatidylserine externalization and microparticle release, were increased following storage at -30 °C or with 3% Me2SO, and 2FA showed no protective effect. Platelet function remained similar regardless of 2FA, although functionality was reduced following storage at -30 °C or with 3% Me2SO compared to standard cryopreserved platelets. While the addition of 2FA to platelets provided a small level of protection for some quality parameters, it was unable to prevent alterations to the majority of in vitro parameters. Therefore, it is unlikely that ice recrystallization is the major cause of cryopreservation-induced damage.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/143839